miR‐200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pigment Cell & Melanoma Research

• Publication date

  2015-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/pcmr.12379PMID 25903073PMCID PMC4597606
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog

  2014cited by this paper
• Polycomb proteins control proliferation and transformation independently of cell cycle checkpoints by regulating DNA replication

  2014cited by this paper
• Chromatin modifying enzymes

  2014cited by this paper
• The role of microRNAs in melanoma.

  2014cited by this paper
• Resistance to BRAF-targeted therapy in melanoma.

  2013cited by this paper
• Chromatin modifying enzymes as modulators of reprogramming

  2012influential reference
• miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression

  2012cited by this paper
• miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.

  2012influential reference
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Abstract 5370: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

  2011cited by this paper
• RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

  2011cited by this paper
• Cancer Therapy : Preclinical MEK-Independent Survival of B-RAFV 600 E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX 4720

  2011cited by this paper
• Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells.

  2011cited by this paper
• Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters

  2011cited by this paper
• Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer

  2011cited by this paper
• Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice

  2011cited by this paper
• Expression patterns of Bmi‐1 and p16 significantly correlate with overall, disease‐specific, and recurrence‐free survival in oropharyngeal squamous cell carcinoma

  2011cited by this paper
• Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases

  2011cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• MicroRNA and drug resistance

  2010cited by this paper
• Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.

  2010cited by this paper
• Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

  2010cited by this paper
• MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720

  2010cited by this paper
• miR-200 Enhances Mouse Breast Cancer Cell Colonization to Form Distant Metastases

  2009cited by this paper
• Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells.

  2009cited by this paper
• The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells.

  2009cited by this paper
• The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs

  2009influential reference
• Mechanism of drug sensitivity and resistance in melanoma.

  2009cited by this paper
• BRafV600E cooperates with Pten silencing to elicit metastatic melanoma

  2009cited by this paper
• Polycomb repression

  2008cited by this paper
• Stem cell protein BMI‐1 is an independent marker for poor prognosis in oligodendroglial tumours

  2008cited by this paper
• The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

  2008cited by this paper
• Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

  2008cited by this paper
• The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.

  2008cited by this paper
• lumi: a pipeline for processing Illumina microarray

  2008cited by this paper
• Downregulated NM23-H1 expression is associated with intracranial invasion of nasopharyngeal carcinoma

  2008cited by this paper
• Involvement of E‐cadherin, β‐catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma

  2007cited by this paper
• Consistent expression of the stem cell renewal factor BMI‐1 in primary and metastatic melanoma

  2007cited by this paper
• Complex networks orchestrate epithelial–mesenchymal transitions

  2006cited by this paper
• Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.

  2005cited by this paper
• Ets proteins in biological control and cancer

  2004cited by this paper
• Selectivity in neurotrophin signaling: theme and variations.

  2003cited by this paper
• Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells

  2003cited by this paper
• Epithelial–mesenchymal transitions in tumour progression

  2002cited by this paper
• Mechanisms of cancer drug resistance.

  2002cited by this paper
• Photoelectrochemical dechlorination of phenols

  2002influential reference
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Polycomb repression: from cellular memory to cellular proliferation and cancer.

  2002cited by this paper
• The stem cell.

  1991cited by this paper
• Tumorigenesis and Neoplastic Progression Snail1 Mediates Hypoxia-Induced Melanoma Progression

  year unknowncited by this paper
• Tumorigenesis and Neoplastic Progression Bmi-1 Is Essential for the Tumorigenicity of Neuroblastoma Cells

  year unknowncited by this paper

• Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer

  2026cites this paper
• The neural crest-associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy.

  2025cites this paper
• MicroRNA-200c promotes trophoblast cell dysfunction via inhibition of PI3K/Akt signaling in unexplained recurrent spontaneous abortion.

  2024cites this paper
• Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential

  2024cites this paper
• miR-876-3p is a tumor suppressor on 9p21 that is inactivated in melanoma and targets ERK

  2024cites this paper
• Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers

  2024cites this paper
• A New Approach to Melanoma Treatment: microRNAs.

  2024cites this paper
• Paradigm of biomarkers in metastatic melanoma (Review)

  2024cites this paper
• miRNAs and related genetic biomarkers according to the WHO glioma classification: From diagnosis to future therapeutic targets

  2023cites this paper
• BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers

  2023cites this paper
• Multi-modal molecular programs regulate melanoma cell state

  2022cites this paper
• Role of miRNA in Melanoma Development and Progression

  2022cites this paper
• BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies

  2022cites this paper
• miR-200c increases the sensitivity of breast cancer cells to Doxorubicin through downregulating MDR1 gene.

  2022cites this paper
• Mechanisms of Resistance to Targeted Therapies in Skin Cancers

  2021cites this paper
• Non-coding RNA dysregulation in skin cancers.

  2021cites this paper
• Non-coding RNAs in melanoma: Biological functions and potential clinical applications

  2021cites this paper
• The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma

  2021cites this paper
• The Anticancer Effect of Inula viscosa Methanol Extract by miRNAs’ Re-regulation: An in vitro Study on Human Malignant Melanoma Cells

  2021cites this paper
• Manipulating immune system using nanoparticles for an effective cancer treatment: Combination of targeted therapy and checkpoint blockage miRNA.

  2020cites this paper
• The miRNAs Role in Melanoma and in Its Resistance to Therapy

  2020cites this paper
• miRNAs as Key Players in the Management of Cutaneous Melanoma

  2020influential citation
• MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors

  2020cites this paper
• Tissue microRNA expression profiling in hepatic and pulmonary metastatic melanoma

  2020cites this paper
• Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review

  2020cites this paper
• miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma

  2020cites this paper
• The Non-Coding Landscape of Cutaneous Malignant Melanoma: A Possible Route to Efficient Targeted Therapy

  2020cites this paper
• Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.

  2019cites this paper
• miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

  2019cites this paper
• Role of miRNAs in Melanoma Metastasis

  2019cites this paper
• R

  2019cites this paper
• MicroRNAs in Melanoma Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors

  2019cites this paper
• The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma

  2018cites this paper
• Biological role of miR-204 and miR-211 in melanoma

  2018cites this paper
• miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.

  2018cites this paper
• A proteomic analysis of an in vitro knock-out of miR-200c

  2018cites this paper
• Interplay between small and long non‐coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces

  2018cites this paper
• miRNAs, Melanoma and Microenvironment: An Intricate Network

  2017cites this paper
• Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.

  2017cites this paper
• Potential use of microRNA-200c as a prognostic marker in non-small cell lung cancer.

  2017cites this paper
• MicroRNA‐125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway

  2017cites this paper
• MicroRNAs in melanoma development and resistance to target therapy

  2017cites this paper
• Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma

  2017cites this paper
• MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma.

  2017cites this paper
• miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance

  2016cites this paper
• The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.

  2016cites this paper
• miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways

  2016cites this paper
• DNA methylation-induced E-cadherin silencing is correlated with the clinicopathological features of melanoma.

  2016cites this paper
• Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b

  2015cites this paper
• miR-425 inhibits melanoma metastasis through repression of PI3K-Akt pathway by targeting IGF-1.

  2015cites this paper